Antigen News and Research

RSS

Hospitalization and death of H1N1 patients can occur at all ages, says study

In contrast with some common perceptions regarding 2009 influenza A(H1N1) infections, an examination of cases in California indicates that hospitalization and death can occur at all ages, and about 30 percent of hospitalized cases have been severe enough to require treatment in an intensive care unit, according to a study in the November 4 issue of JAMA.

4 Nov 2009

AUA clarifes recommendations on prostate cancer testing with PSA test and DRE

The American Urological Association (AUA) is aware of recent news reports disparaging prostate cancer testing. We are concerned that these reports are causing significant confusion for patients and we wish to clarify our recommendations on prostate cancer testing with the prostate-specific antigen (PSA) test and digital rectal exam (DRE). The AUA strongly supports early prostate cancer detection and feels it is in a man's best interest to consider being tested for prostate cancer.

4 Nov 2009

Blood vessels good indicators of prostate cancer behavior

A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous treatment, or slowly, allowing therapy and its risks to be safely delayed?

4 Nov 2009

Mechanical force switches T cell from disease-scanning to disease-fighting mode

The immune system's T cells have the unique responsibilities of being both jury and executioner. They examine other cells for signs of disease, including cancers or infections, and, if such evidence is found, rid them from the body. Precisely how T cells shift so swiftly from one role to another, however, has been a mystery.

3 Nov 2009

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.

2 Nov 2009

Scientists present new perspective on antigenic drift of flu viruses

Influenza viruses evade infection-fighting antibodies by constantly changing the shape of their major surface protein. This shape-shifting, called antigenic drift, is why influenza vaccines-which are designed to elicit antibodies matched to each year's circulating virus strains-must be reformulated annually.

30 Oct 2009

Helper T cell's effect raises possibility of cellular therapy and vaccine development

A specific type of T helper cell awakens the immune system to the stealthy threat of cancer and triggers an attack of killer T cells custom-made to destroy the tumors, scientists from The University of Texas M. D. Anderson Cancer Center report in the early online edition of the journal Immunity.

30 Oct 2009

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies.

30 Oct 2009

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.

29 Oct 2009

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

28 Oct 2009

3M launches new Rapid Detection Respiratory Syncytial Virus Test

Expanding its platform of rapid diagnostic testing, 3M today announced the introduction of the 3M™ Rapid Detection RSV Test. RSV, or respiratory syncytial virus, is a respiratory virus that infects the lungs and breathing passages and is a common cause of bronchitis and pneumonia in children under one year.

28 Oct 2009

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Precision Antibody(TM) has been selected as the antibody developer for a component of the National Cancer Institute (NCI)'s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

28 Oct 2009

D3 FastPoint L-DFA Influenza A/ Influenza B Virus Identification Kit receives FDA clearance

Diagnostic Hybrids, a leading developer of in vitro diagnostic fluorescent staining kits and cell culture products, announces the U.S. Food and Drug Administration (FDA) (510k) clearance of its D3 FastPointTM L-DFATM Influenza A/ Influenza B Virus Identification Kit, which allows for the identification of influenza A virus and influenza B virus from a patient’s specimen in under 30 minutes.

28 Oct 2009

Roche's high-throughput sequencing technology used for high-resolution HLA genotyping

A study published this month in the journal Tissue Antigens reports that researchers at Roche Molecular Systems in Pleasanton, CA have used high-throughput sequencing technology from 454 Life Sciences, a Roche Company, to carry out high-resolution human leukocyte antigen (HLA) genotyping in research samples.

27 Oct 2009

Mechanisms to control protein organization and cell-cell interaction in the immune system discovered

In a process essential to the immune system's response to infection, dendritic cells responsible for identifying pathogens communicate with the T-cells that destroy the infectious agents. To achieve this, the dendritic cells must be correctly activated and migrate to the lymph nodes where they must adhere firmly to T-cells.

27 Oct 2009

Progenika to provide blood group genotyping reference laboratory services to ARUP

Progenika, Inc. today announced that it has entered into an agreement with ARUP Laboratories (ARUP) of Salt Lake City, UT, to provide blood group genotyping reference laboratory services to ARUP to determine patient red blood cell antigen profiles when serology has logistic and functional limitations.

22 Oct 2009

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden.

21 Oct 2009

Carcinoembryonic antigen co-discoverer Dr. Phil Gold to be inducted into The Canadian Medical Hall of Fame

Prof. Heather Munroe-Blum, Principal and Vice-Chancellor of McGill University, and the Hon. Arthur T. Porter, Director General and CEO of the McGill University Health Centre (MUHC), welcome the news that Dr. Phil Gold is to be inducted into The Canadian Medical Hall of Fame. In 1965, Dr. Gold co-discovered the carcinoembryonic antigen (CEA), the first clinically useful human tumour marker that revolutionized the diagnosis and management of cancer.

21 Oct 2009

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 80% during its first three months of measurement. The CI Index as a whole trades for 10% of estimated future revenues.

21 Oct 2009

New tools needed to identify men and women at risk for the most aggressive cancers

Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association."

21 Oct 2009

Antigen News and Research

Hospitalization and death of H1N1 patients can occur at all ages, says study

AUA clarifes recommendations on prostate cancer testing with PSA test and DRE

Blood vessels good indicators of prostate cancer behavior

Mechanical force switches T cell from disease-scanning to disease-fighting mode

Gilead Sciences to present Viread Phase III clinical trial data

Scientists present new perspective on antigenic drift of flu viruses

Helper T cell's effect raises possibility of cellular therapy and vaccine development

Studies demonstrate that investigational cancer vaccines show encouraging immune response rates

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Pure Protein develops soluble Class II human leukocyte antigens

3M launches new Rapid Detection Respiratory Syncytial Virus Test

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

D3 FastPoint L-DFA Influenza A/ Influenza B Virus Identification Kit receives FDA clearance

Roche's high-throughput sequencing technology used for high-resolution HLA genotyping

Mechanisms to control protein organization and cell-cell interaction in the immune system discovered

Progenika to provide blood group genotyping reference laboratory services to ARUP

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Carcinoembryonic antigen co-discoverer Dr. Phil Gold to be inducted into The Canadian Medical Hall of Fame

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

New tools needed to identify men and women at risk for the most aggressive cancers

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News